What question did this study set out to answer?

To explore the relationship between pulmonary function and health-related quality of life in NSCLC patients during treatment.

March 22, 2026Open Access

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

Key Points

To explore the relationship between pulmonary function and health-related quality of life in NSCLC patients during treatment.
Assess pulmonary function in stage III NSCLC patients receiving chemoradiotherapy and durvalumab.
Monitor health-related quality of life using standardized measures during treatment.
Analyze associations between lung function and quality of life metrics.
Health-related quality of life remained stable during treatment.
Impaired lung function was linked to lower health-related quality of life scores.
Further research is required to investigate subgroup effects.

Abstract

The HRQoL remained stable during chemoradiotherapy and durvalumab treatment in stage III NSCLC patients. Impaired lung function was associated with modestly lower HRQoL, though larger studies are needed to confirm subgroup effects.

Bookmark

View Full Paper

Cite This Study

Sommervoll et al. (Thu,) studied this question.

synapsesocial.com/papers/69bf86ecf665edcd009e90c9 https://doi.org/https://doi.org/10.2340/1651-226x.2026.45040

Bookmark

View Full Paper